Hypertension and diabetes

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 2, 2002, Pages 221-228

  Jandeleit Dahm, Karin ^a   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; TRANDOLAPRIL;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION;

EID: 0036191911     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200203000-00014     Document Type: Review

References (74)

1. Optimizing treatment of hypertension in patients with diabetes
2. Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients
3. Improvement in hypertension in patients with diabetes mellitus after kidney/pancreas transplantation
4. Insulin resistance: The shape of things to come
5. Diabetes, hypertension, and cardiovascular disease: An update
6. Cardiovascular morbidity and mortality associated with the metabolic syndrome
7. Risk factor clustering in hypertensive patients: Impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines
8. Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats
9. Cross-talk between the insulin and angiotensin signaling systems
10. Pathogenesis, prevention and treatment of diabetic nephropathy
11. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
12. Angiotensin II and its receptors in the diabetic kidney
13. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
14. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat
15. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat
16. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
17. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
18. Mechanisms underlying renoprotection during renin-angiotensin system blockade
19. Aldosterone in renal disease
20. Nephrin is specifically located at the slit diaphragm of glomerular podocytes
21. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension
22. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats
23. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone
24. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy
25. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
26. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria
27. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure
28. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: Results of a randomized controlled trial
29. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy
30. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
31. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine
32. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
33. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
34. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
35. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
36. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
37. The role of angiotensin II and bradykinin in diabetic nephropathy: Functional and structural studies
38. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
39. The role of angiotensin II receptor antagonists in the management of diabetes
40. Preserving renal function in adults with hypertension and diabetes: A consensus approach
41. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and Lisinopril microalbuminuria (CALM) study
42. Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy
43. Primary prevention of renal failure in diabetic patients: The Bergamo Nephrologic Diabetes Complication Trial
44. Independent association of high blood pressure and aortic atherosclerosis: A population-based study
45. The importance of age and obesity on the relation between diabetes and left ventricular mass
46. Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries
47. Impact at left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus
48. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study)
49. Myocardial cell death in human diabetes
50. Augmentation of central arterial pressure in Type 2 diabetes
51. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
52. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys
53. Breakers of advanced glycation end products restore large artery properties in experimental diabetes
54. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
55. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
56. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
57. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
58. High blood pressure and diabetes mellitus: Are all antihypertensive drugs created equal?
59. Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst-Eur) trial
60. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients
61. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
62. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intraocular renin-angiotensin system
63. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
64. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats
65. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
66. Retinal neovascularization is prevented by blockade of the renin-angiotensin system
67. Effect of lisinopril on progression of retinopathy in people with type 1 diabetes
68. The Diabetic Retinopathy Candesartan Trial (DIRECT) programme
69. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
70. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
71. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
72. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
73. ADVANCE: Action in diabetes and vascular disease: Preterax and diamicron MR controlled evaluation. Study design and rationale
74. Progress in cardiovascular biology: PPAR for the course